Impact of Cannabis on Opioid Self-Administration
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with moderate to severe opioid use disorder who experience opioid withdrawal
- •No allergies or adverse reactions to cannabis or opioids
- •Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks
排除标准
- •Individuals seeking treatment for opioid use disorder
研究组 & 干预措施
Placebo Cannabis
Participants receive placebo cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Placebo Cannabis (Drug)
Active Cannabis
Participants receive active cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Intranasal Opioid Agonist (Drug)
Active Cannabis
Participants receive active cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Oral Opioid Agonist (Drug)
Placebo Cannabis
Participants receive placebo cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Intranasal Opioid Agonist (Drug)
Placebo Cannabis
Participants receive placebo cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Oral Opioid Agonist (Drug)
Active Cannabis
Participants receive active cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
干预措施: Cannabis (Drug)
研究者
Shanna Babalonis, PhD
Associate Professor
University of Kentucky